<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445900</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000530973</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC028A</secondary_id>
    <secondary_id>1360-03</secondary_id>
    <nct_id>NCT00445900</nct_id>
  </id_info>
  <brief_title>Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia</brief_title>
  <official_title>Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide (&quot;TPC&quot;) in the Therapy of Myelofibrosis With Myeloid Metaplasia (MMM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving thalidomide together with prednisone and cyclophosphamide may lessen&#xD;
      symptoms caused by myelofibrosis and myeloid metaplasia.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving thalidomide&#xD;
      together with prednisone and cyclophosphamide works in treating patients with myelofibrosis&#xD;
      and myeloid metaplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the benefit of thalidomide, prednisone, and cyclophosphamide in alleviating&#xD;
           disease-associated anemia, thrombocytopenia, and/or splenomegaly in patients with&#xD;
           myelofibrosis with myeloid metaplasia (MMM).&#xD;
&#xD;
        -  Determine the benefit of this regimen in palliating four hypercatabolic constitutional&#xD;
           symptoms (i.e., weight loss, fatigue, drenching night sweats, and unexplained fevers) in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effect of this regimen on leukocyte count.&#xD;
&#xD;
        -  Determine the effect of this regimen on bone marrow histology, including microvessel&#xD;
           density and reticulin fibrosis.&#xD;
&#xD;
        -  Determine the effect of this regimen on intramedullary and urinary markers of&#xD;
           angiogenesis.&#xD;
&#xD;
        -  Determine the effect of this regimen on circulating myeloid progenitor cells by&#xD;
           quantifying CD34+ cells.&#xD;
&#xD;
      OUTLINE: Patients receive oral thalidomide, oral prednisone, and oral cyclophosphamide (TPC)&#xD;
      once daily on days 1-28. Treatment repeats every 28 days for 3 courses. After 3 courses (3&#xD;
      months) of treatment, patients who respond to TPC therapy may receive oral thalidomide alone&#xD;
      once daily for up to 3 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo bone marrow aspirate and biopsy prior to study entry, 6 months after&#xD;
      starting therapy, and then every 6 months for up to 3 years. Samples are analyzed by&#xD;
      microvessel density/angiogenesis studies (i.e., CD34 immunohistochemical and vascular&#xD;
      endothelium-specific staining) to determine the effect of therapy on markers of bone marrow&#xD;
      angiogenesis.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 6 months for up to 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed response, defined as a complete or partial response in ≥ 1 of 3 response categories (i.e., anemia, thrombocytopenia, or splenomegaly or hepatomegaly)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Constitutional symptom status and bone marrow morphology</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by NCI CTC v 2.0</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Secondary Myelofibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed myelofibrosis with myeloid metaplasia (MMM) of any of the&#xD;
             following subtypes:&#xD;
&#xD;
               -  Agnogenic myeloid metaplasia&#xD;
&#xD;
               -  Post-polycythemic myeloid metaplasia&#xD;
&#xD;
               -  Post-thrombocythemic myeloid metaplasia&#xD;
&#xD;
          -  Must have 1 of the following MMM-related conditions:&#xD;
&#xD;
               -  Anemia, defined as hemoglobin &lt; 10 g/dL&#xD;
&#xD;
                    -  Iron deficiency must be excluded as cause&#xD;
&#xD;
               -  Thrombocytopenia, defined as platelet count &lt; 100,000/mm³&#xD;
&#xD;
               -  Palpable hepatomegaly or splenomegaly&#xD;
&#xD;
          -  No evidence of myelofibrosis-associated conditions in the bone marrow, including any&#xD;
             of the following:&#xD;
&#xD;
               -  Metastatic carcinoma&#xD;
&#xD;
               -  Lymphoma&#xD;
&#xD;
               -  Myelodysplasia&#xD;
&#xD;
               -  Hairy cell leukemia&#xD;
&#xD;
               -  Mast cell disease&#xD;
&#xD;
               -  Acute leukemia (including M7 type)&#xD;
&#xD;
               -  Acute myelofibrosis&#xD;
&#xD;
          -  No chromosomal translocation t(9:22) or bcr-abl as determined by bone marrow&#xD;
             chromosome analysis or peripheral blood fluorescent in situ hybridization (FISH)&#xD;
             analysis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 750/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 2 times upper limit of normal (ULN), unless elevation due to MMM&#xD;
&#xD;
          -  AST ≤ 5 times ULN, unless elevation due to MMM&#xD;
&#xD;
          -  Creatinine ≤ 2.5 mg/dL&#xD;
&#xD;
          -  No uncontrolled infection, including tuberculosis&#xD;
&#xD;
               -  No known history of positive purified protein derivative (PPD) untreated by&#xD;
                  isoniazid therapy&#xD;
&#xD;
                    -  Positive PPD with normal chest X-ray and completion of full-course isoniazid&#xD;
                       therapy allowed&#xD;
&#xD;
          -  No federal medical center inmates or other incarcerated patients&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No comorbid condition in which the use of study therapy is felt to be potentially&#xD;
             harmful&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 forms of effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No chemotherapy (e.g., hydroxyurea, myelosuppressive therapy) within the past 14 days&#xD;
&#xD;
          -  Prior splenectomy for MMM allowed&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben A. Mesa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <last_update_submitted>March 16, 2011</last_update_submitted>
  <last_update_submitted_qc>March 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ruben A. Mesa, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>primary myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>secondary myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

